Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

Investigational

1

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Tyrosine 3-hydroxylase

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1979

2

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Pheochromocytoma

2

Diabetes mellitus

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Valeant

2

Lenart, G.H.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

4

EPA CompTox

3

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHYPERTENSIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTIHYPERTENSIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Tyrosine hydroxylase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

METYROSINE

DOQ0J0TPF7

Export Data
Search for Structure

Status:

US Approved Rx (1979)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Tyrosine 3-hydroxylase

Conditions:

Pheochromocytoma

Metirosine is an antihypertensive drug. Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is als...

o the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure. Metirosine is used for the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.

PICONOL

7HQ8UT1TPS

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Diabetes mellitus

Piconol (2-Pyridinemethanol) is a pyridylalcohol devivative with hypoglycemic activity.

O-(BENZOTRIAZOL-1-YL)-N,N,N',N'-TETRAMETHYLURONIUM HEXAFLUOROPHOSPHATE

X5I03TZQ8D

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

METYROSINE HYDROCHLORIDE

094DKY9OHM

Export Data
Search for Structure

Status:

US Approved Rx (1979)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Tyrosine 3-hydroxylase

Conditions:

Pheochromocytoma

Metirosine is an antihypertensive drug. Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is als...

o the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure. Metirosine is used for the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1